CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 129 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $12 | -7.7% | 273 | 0.0% | 0.00% | – |
Q1 2024 | $13 | +30.0% | 273 | 0.0% | 0.00% | – |
Q4 2023 | $10 | +66.7% | 273 | +37.2% | 0.00% | – |
Q3 2023 | $6 | +50.0% | 199 | 0.0% | 0.00% | – |
Q2 2023 | $4 | +33.3% | 199 | 0.0% | 0.00% | – |
Q1 2023 | $3 | -25.0% | 199 | 0.0% | 0.00% | – |
Q4 2022 | $4 | -99.9% | 199 | 0.0% | 0.00% | – |
Q3 2022 | $4,000 | 0.0% | 199 | 0.0% | 0.00% | – |
Q2 2022 | $4,000 | +33.3% | 199 | +50.8% | 0.00% | – |
Q1 2022 | $3,000 | -25.0% | 132 | 0.0% | 0.00% | – |
Q4 2021 | $4,000 | +33.3% | 132 | 0.0% | 0.00% | – |
Q3 2021 | $3,000 | +200.0% | 132 | +112.9% | 0.00% | – |
Q2 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q1 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
Q4 2020 | $1,000 | -50.0% | 62 | -59.5% | 0.00% | – |
Q3 2019 | $2,000 | -50.0% | 153 | 0.0% | 0.00% | – |
Q2 2019 | $4,000 | +33.3% | 153 | 0.0% | 0.00% | – |
Q1 2019 | $3,000 | -57.1% | 153 | -30.5% | 0.00% | – |
Q4 2018 | $7,000 | – | 220 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |